{"nctId":"NCT01219855","briefTitle":"Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)","startDateStruct":{"date":"2010-10"},"conditions":["Chronic Kidney Disease","Secondary Hyperparathyroidism","Vitamin D Insufficiency"],"count":78,"armGroups":[{"label":"Cohort 1: CTAP101 Capsules 60µg","type":"EXPERIMENTAL","interventionNames":["Drug: Cohort 1 CTAP101 Capsules- 60µg"]},{"label":"Cohort 1: CTAP101 Capsules 90µg","type":"EXPERIMENTAL","interventionNames":["Drug: Cohort 1 CTAP101 Capsules - 90µg"]},{"label":"Cohort 1: Sugar Capsule","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Cohort 1 Matching Sugar Capsule"]},{"label":"Cohort 2: CTAP101 Capsules 30µg","type":"EXPERIMENTAL","interventionNames":["Drug: Cohort 2 CTAP101 Capsules - 30µg"]},{"label":"Cohort 2: Sugar Capsule","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Cohort 2 Matching Sugar Capsule"]}],"interventions":[{"name":"Cohort 1 CTAP101 Capsules- 60µg","otherNames":[]},{"name":"Cohort 1 CTAP101 Capsules - 90µg","otherNames":[]},{"name":"Cohort 1 Matching Sugar Capsule","otherNames":[]},{"name":"Cohort 2 CTAP101 Capsules - 30µg","otherNames":[]},{"name":"Cohort 2 Matching Sugar Capsule","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Urinary albumin excretion of ≤3000 μg of creatinine\n2. Stage 3 CKD\n3. Plasma iPTH: \\> 70 pg/mL and \\< 500 pg/mL\n4. Serum Ca: ≥ 8.4 mg/dL and \\< 10.0 mg/dL\n5. Serum P: ≥ 2.0 mg/dL and \\< 5.0 mg/dL\n6. Serum 25-hydroxyvitamin D: \\> 10 ng/mL and \\< 29 ng/mL.\n7. Discontinue vitamin D use for duration of study\n\nExclusion Criteria:\n\n1. History of kidney transplant or parathyroidectomy\n2. Spot urine calcium:creatinine ratio \\> 0.2\n3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event or hepatitis\n4. Currently on dialysis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).","description":"The proportion of subjects in the per protocol population with serum 25-hydroxyvitamin D ≥30 ng/mL at End-of-Treatment (EOT; Week 6) in Cohorts 1 and 2 (60/90 and 30 μg groups, respectively) were compared to their corresponding placebo groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"91.7","spread":null},{"groupId":"OG004","value":"7.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population)","description":"Mean percent change from baseline in plasma intact parathyroid hormone (iPTH) from baseline to End of Treatment (EOT) in the Per Protocol population. Subjects in Cohorts 1 and 2 (dose regimens 60/90 and 30 mcg, respectively) were compared to their respective placebo groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.77","spread":"22.778"},{"groupId":"OG001","value":"-39.32","spread":"16.243"},{"groupId":"OG002","value":"20.49","spread":"52.871"},{"groupId":"OG003","value":"-20.86","spread":"21.549"},{"groupId":"OG004","value":"13.18","spread":"30.185"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum 25-hydroxyvitamin D at Week 6","description":"Mean absolute change from baseline in serum total 25-hydroxyvitamin D to end of treatment (EOT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.25","spread":"16.519"},{"groupId":"OG001","value":"63.69","spread":"17.826"},{"groupId":"OG002","value":"-0.65","spread":"2.502"},{"groupId":"OG003","value":"16.22","spread":"6.005"},{"groupId":"OG004","value":"-1.89","spread":"4.913"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum 25-hydroxyvitamin D at End of Treatment (EOT, Week 6) in the Per Protocol Population","description":"Mean percent change from baseline in serum 25-hydroxyvitamin D at End of Treatment (EOT, week 6) in the per protocol population. Subjects in Cohorts 1 and 2 (dose regimens of 60/90 and 30 mcg, respectively) were compared versus their corresponding placebo groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187.64","spread":"74.251"},{"groupId":"OG001","value":"313.12","spread":"101.592"},{"groupId":"OG002","value":"-2.67","spread":"13.069"},{"groupId":"OG003","value":"90.90","spread":"62.189"},{"groupId":"OG004","value":"-7.22","spread":"20.599"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 30% at Week 6","description":"Proportion of subjects with at least 30% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Reduction of Intact Parathyroid Hormone (iPTH) of at Least 20% at Week 6","description":"Proportion of subjects with at least 20% reduction in plasma intact parathyroid hormone (iPTH) and/or mean iPTH reduction to 70 pg/mL or less at End of Treatment (EOT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["Oedema peripheral","Contusion","Headache","Gout","Abdominal discomfort"]}}}